Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019027973) TREATMENTS FOR A HEMATOLOGICAL MALIGNANCY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/027973 International Application No.: PCT/US2018/044531
Publication Date: 07.02.2019 International Filing Date: 31.07.2018
IPC:
A61K 39/395 (2006.01) ,A61K 47/48 (2006.01) ,A61K 51/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
48
the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51
Preparations containing radioactive substances for use in therapy or testing in vivo
Applicants:
ACTINIUM PHARMACEUTICALS INC. [US/US]; 275 Madison Avenue, 7th Floor New York, NY 10016, US
Inventors:
SETH, Sandesh; US
THOMAS, Keisha; US
Agent:
DUKES, Michael E.; US
Priority Data:
62/539,11431.07.2017US
Title (EN) TREATMENTS FOR A HEMATOLOGICAL MALIGNANCY
(FR) TRAITEMENTS POUR UNE MALIGNITÉ HÉMATOLOGIQUE
Abstract:
(EN) Pharmaceutical compositions comprising a radionuclide labelled monoclonal antibody against CD38, and methods of treating a hematological malignancy, inhibiting growth and/or proliferation of a cell expressing CD38, or treating a disease or disorder involving cells expressing CD38 are disclosed. An exemplary monoclonal antibody includes daratumumab labeled with actinium (225Ac).
(FR) L'invention concerne des compositions pharmaceutiques comprenant un anticorps monoclonal marqué par un radionucléide contre le CD38, et des méthodes de traitement d'une malignité hématologique, d'inhibition de la croissance et/ou de la prolifération d'une cellule exprimant le CD38, ou de traitement d'une maladie ou d'un trouble impliquant des cellules exprimant le CD38. Un exemple d'anticorps monoclonal comprend du daratumumab marqué par l'actinium (225Ac).
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)